drugset / Trial / NCT02411604

Expanded Access Study for Renal Transplant Patients With Envarsus XR ™

NCT02411604

Expanded access Approved for marketing Veloxis Pharmaceuticals

Summary

Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR (Tacrolimus).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Tacrolimus Small molecule

Indications